Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Klag

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Zeitschrift Fur Gastroenterologie|February 5, 2020
Infodemiology of Crohn's disease and Ulcerative colitis using Google Trends - an approach to investigate patient needsRonald Keller, Stefano Fusco, Eduard F Stange, et al.
International Journal of Colorectal Disease|December 1, 2018
Enterocutaneous fistula in severely active Crohn's disease: preoperative anti-TNF alpha treatment to limit bowel resection-report of a casePeter Wilhelm, Andreas Kirschniak, Jonas Johannink, et al.
Journal of Gastrointestinal Cancer|May 2, 2022
Chromoendoscopy in Combination with Random Biopsies for Patients with Pathogenic CDH1 Mutations Undergoing Endoscopic SurveillanceBenjamin Ruf, Cristiana Roggia, Christopher Schroeder, et al.
Zeitschrift Fur Gastroenterologie|February 14, 2017
Low-grade appendiceal mucinous neoplasm (LAMN) - 3-year endoscopic follow-up underlines benign course of LAMN type 1Thomas Klag, Jan Wehkamp, Hans Bösmüller, et al.
Intestinal Research|February 26, 2020
Quality of life in inflammatory bowel diseases: it is not all about the bowelRonald Keller, Nazar Mazurak, Laura Fantasia, et al.
Inflammatory Intestinal Diseases|March 2, 2019
Tacrolimus Suppositories in Therapy-Resistant Ulcerative ProctitisSimon U Jaeger, Thomas Klag, Katharina Hoeger, et al.
Journal of Cancer Research and Clinical Oncology|November 18, 2011
Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicityNicolai Härtel, Thomas Klag, Benjamin Hanfstein, et al.
Therapeutic Advances in Gastroenterology|October 27, 2018
GLP-2 analog teduglutide significantly reduces need for parenteral nutrition and stool frequency in a real-life settingMarc Schoeler, Thomas Klag, Judith Wendler, et al.
Inflammatory Intestinal Diseases|March 2, 2019
Human Endogenous Retroviruses: Residues of Ancient Times Are Differentially Expressed in Crohn's DiseaseThomas Klag, Lioba Courth, Maureen J Ostaff, et al.
Annals of Hematology|April 30, 2013
Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinibPaul La Rosée, Philippe Martiat, Armin Leitner, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Zeitschrift Fur Gastroenterologie|February 5, 2020
Infodemiology of Crohn's disease and Ulcerative colitis using Google Trends - an approach to investigate patient needsRonald Keller, Stefano Fusco, Eduard F Stange, et al.
International Journal of Colorectal Disease|December 1, 2018
Enterocutaneous fistula in severely active Crohn's disease: preoperative anti-TNF alpha treatment to limit bowel resection-report of a casePeter Wilhelm, Andreas Kirschniak, Jonas Johannink, et al.
Journal of Gastrointestinal Cancer|May 2, 2022
Chromoendoscopy in Combination with Random Biopsies for Patients with Pathogenic CDH1 Mutations Undergoing Endoscopic SurveillanceBenjamin Ruf, Cristiana Roggia, Christopher Schroeder, et al.
Zeitschrift Fur Gastroenterologie|February 14, 2017
Low-grade appendiceal mucinous neoplasm (LAMN) - 3-year endoscopic follow-up underlines benign course of LAMN type 1Thomas Klag, Jan Wehkamp, Hans Bösmüller, et al.
Intestinal Research|February 26, 2020
Quality of life in inflammatory bowel diseases: it is not all about the bowelRonald Keller, Nazar Mazurak, Laura Fantasia, et al.
Inflammatory Intestinal Diseases|March 2, 2019
Tacrolimus Suppositories in Therapy-Resistant Ulcerative ProctitisSimon U Jaeger, Thomas Klag, Katharina Hoeger, et al.
Journal of Cancer Research and Clinical Oncology|November 18, 2011
Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicityNicolai Härtel, Thomas Klag, Benjamin Hanfstein, et al.
Therapeutic Advances in Gastroenterology|October 27, 2018
GLP-2 analog teduglutide significantly reduces need for parenteral nutrition and stool frequency in a real-life settingMarc Schoeler, Thomas Klag, Judith Wendler, et al.
Inflammatory Intestinal Diseases|March 2, 2019
Human Endogenous Retroviruses: Residues of Ancient Times Are Differentially Expressed in Crohn's DiseaseThomas Klag, Lioba Courth, Maureen J Ostaff, et al.
Annals of Hematology|April 30, 2013
Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinibPaul La Rosée, Philippe Martiat, Armin Leitner, et al.
Pageof 3